This is fantastic. Particularly enthralled to read this:
"The major incentive afforded to a product with QIDP status is an additional 5 years of regulatory
exclusivity, on top of the standard regulatory exclusivity that comes with FDA approval of a New Drug
Application (NDA). This incentive could potentially enhance the value of a successful product as it
provides an extra 5 years of protection, during which period, generics cannot enter the market."
Ann: FDA Qualified Infectious Disease Product Status for BTX 1801, page-16
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.0¢ | $1.603M | 4.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 378157 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 98000 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |